23andMe Holding Co. (ME) Stock Competitors & Peer Comparison
See (ME) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ME | $0.61 | +0.00% | 15.3M | -0.03 | -$17.39 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.75% |
| TMO | $482.08 | -2.42% | 179.2B | 26.53 | $18.17 | +0.36% |
| DHR | $176.11 | -2.09% | 124.6B | 34.13 | $5.16 | +0.75% |
| IDXX | $550.82 | -2.82% | 43.5B | 40.56 | $13.58 | N/A |
| A | $135.05 | -0.68% | 38.2B | 27.17 | $4.97 | +0.56% |
| NTRA | $212.73 | -2.78% | 30.5B | -130.47 | -$1.63 | N/A |
| IQV | $180.64 | -3.31% | 30.1B | 22.44 | $8.05 | N/A |
| ILMN | $162.55 | -1.13% | 24.6B | 29.52 | $5.51 | N/A |
| WAT | $371.93 | -1.65% | 24.2B | 47.30 | $7.86 | N/A |
Stock Comparison
ME vs DHR-PB Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ME is priced at $0.61, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ME's ROE is -7.71%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, ME is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DHR-PB's competition here
ME vs TMO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, TMO has a market cap of 179.2B. Regarding current trading prices, ME is priced at $0.61, while TMO trades at $482.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas TMO's P/E ratio is 26.53. In terms of profitability, ME's ROE is -7.71%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ME is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check TMO's competition here
ME vs DHR Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DHR has a market cap of 124.6B. Regarding current trading prices, ME is priced at $0.61, while DHR trades at $176.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DHR's P/E ratio is 34.13. In terms of profitability, ME's ROE is -7.71%, compared to DHR's ROE of +0.07%. Regarding short-term risk, ME is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DHR's competition here
ME vs IDXX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, IDXX has a market cap of 43.5B. Regarding current trading prices, ME is priced at $0.61, while IDXX trades at $550.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas IDXX's P/E ratio is 40.56. In terms of profitability, ME's ROE is -7.71%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, ME is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check IDXX's competition here
ME vs A Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, A has a market cap of 38.2B. Regarding current trading prices, ME is priced at $0.61, while A trades at $135.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas A's P/E ratio is 27.17. In terms of profitability, ME's ROE is -7.71%, compared to A's ROE of +0.21%. Regarding short-term risk, ME is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check A's competition here
ME vs NTRA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NTRA has a market cap of 30.5B. Regarding current trading prices, ME is priced at $0.61, while NTRA trades at $212.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NTRA's P/E ratio is -130.47. In terms of profitability, ME's ROE is -7.71%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, ME is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NTRA's competition here
ME vs IQV Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, IQV has a market cap of 30.1B. Regarding current trading prices, ME is priced at $0.61, while IQV trades at $180.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas IQV's P/E ratio is 22.44. In terms of profitability, ME's ROE is -7.71%, compared to IQV's ROE of +0.22%. Regarding short-term risk, ME is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check IQV's competition here
ME vs ILMN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ILMN has a market cap of 24.6B. Regarding current trading prices, ME is priced at $0.61, while ILMN trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ILMN's P/E ratio is 29.52. In terms of profitability, ME's ROE is -7.71%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, ME is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ILMN's competition here
ME vs WAT Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, WAT has a market cap of 24.2B. Regarding current trading prices, ME is priced at $0.61, while WAT trades at $371.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas WAT's P/E ratio is 47.30. In terms of profitability, ME's ROE is -7.71%, compared to WAT's ROE of +0.08%. Regarding short-term risk, ME is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check WAT's competition here
ME vs MTD Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MTD has a market cap of 23.6B. Regarding current trading prices, ME is priced at $0.61, while MTD trades at $1,170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MTD's P/E ratio is 27.46. In terms of profitability, ME's ROE is -7.71%, compared to MTD's ROE of -6.10%. Regarding short-term risk, ME is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MTD's competition here
ME vs DGX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DGX has a market cap of 21.4B. Regarding current trading prices, ME is priced at $0.61, while DGX trades at $193.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DGX's P/E ratio is 21.37. In terms of profitability, ME's ROE is -7.71%, compared to DGX's ROE of +0.14%. Regarding short-term risk, ME is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DGX's competition here
ME vs LH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, LH has a market cap of 21.1B. Regarding current trading prices, ME is priced at $0.61, while LH trades at $257.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas LH's P/E ratio is 22.83. In terms of profitability, ME's ROE is -7.71%, compared to LH's ROE of +0.11%. Regarding short-term risk, ME is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check LH's competition here
ME vs EXAS Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, ME is priced at $0.61, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas EXAS's P/E ratio is -95.37. In terms of profitability, ME's ROE is -7.71%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, ME and EXAS have similar daily volatility (0.00).Check EXAS's competition here
ME vs GH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, GH has a market cap of 17.3B. Regarding current trading prices, ME is priced at $0.61, while GH trades at $130.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas GH's P/E ratio is -38.29. In terms of profitability, ME's ROE is -7.71%, compared to GH's ROE of +1.84%. Regarding short-term risk, ME is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check GH's competition here
ME vs PKI Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ME is priced at $0.61, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PKI's P/E ratio is 41.45. In terms of profitability, ME's ROE is -7.71%, compared to PKI's ROE of +0.03%. Regarding short-term risk, ME is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PKI's competition here
ME vs MEDP Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MEDP has a market cap of 12.7B. Regarding current trading prices, ME is priced at $0.61, while MEDP trades at $445.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MEDP's P/E ratio is 28.06. In terms of profitability, ME's ROE is -7.71%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, ME is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MEDP's competition here
ME vs RVTY Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, RVTY has a market cap of 11.2B. Regarding current trading prices, ME is priced at $0.61, while RVTY trades at $100.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas RVTY's P/E ratio is 48.29. In terms of profitability, ME's ROE is -7.71%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, ME is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check RVTY's competition here
ME vs ICLR Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ICLR has a market cap of 10.5B. Regarding current trading prices, ME is priced at $0.61, while ICLR trades at $137.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ICLR's P/E ratio is 47.43. In terms of profitability, ME's ROE is -7.71%, compared to ICLR's ROE of +0.02%. Regarding short-term risk, ME is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ICLR's competition here
ME vs CRL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CRL has a market cap of 8.4B. Regarding current trading prices, ME is priced at $0.61, while CRL trades at $174.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CRL's P/E ratio is -47.21. In terms of profitability, ME's ROE is -7.71%, compared to CRL's ROE of -0.06%. Regarding short-term risk, ME is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CRL's competition here
ME vs QGEN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, QGEN has a market cap of 7.4B. Regarding current trading prices, ME is priced at $0.61, while QGEN trades at $35.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas QGEN's P/E ratio is 18.20. In terms of profitability, ME's ROE is -7.71%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, ME is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check QGEN's competition here
ME vs SYNH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ME is priced at $0.61, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ME's ROE is -7.71%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ME is less volatile compared to SYNH. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check SYNH's competition here
ME vs TWST Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, TWST has a market cap of 4.4B. Regarding current trading prices, ME is priced at $0.61, while TWST trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas TWST's P/E ratio is -53.22. In terms of profitability, ME's ROE is -7.71%, compared to TWST's ROE of -0.17%. Regarding short-term risk, ME is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check TWST's competition here
ME vs BLLN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BLLN has a market cap of 4.3B. Regarding current trading prices, ME is priced at $0.61, while BLLN trades at $94.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BLLN's P/E ratio is 174.44. In terms of profitability, ME's ROE is -7.71%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, ME is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BLLN's competition here
ME vs SHC Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, SHC has a market cap of 4.3B. Regarding current trading prices, ME is priced at $0.61, while SHC trades at $15.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas SHC's P/E ratio is 36.63. In terms of profitability, ME's ROE is -7.71%, compared to SHC's ROE of +0.21%. Regarding short-term risk, ME is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check SHC's competition here
ME vs RDNT Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, ME is priced at $0.61, while RDNT trades at $54.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas RDNT's P/E ratio is -319.47. In terms of profitability, ME's ROE is -7.71%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, ME is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check RDNT's competition here
ME vs OLK Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ME is priced at $0.61, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas OLK's P/E ratio is -96.59. In terms of profitability, ME's ROE is -7.71%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ME is less volatile compared to OLK. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check OLK's competition here
ME vs GRAL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, ME is priced at $0.61, while GRAL trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas GRAL's P/E ratio is -5.82. In terms of profitability, ME's ROE is -7.71%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, ME is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check GRAL's competition here
ME vs NEOG Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NEOG has a market cap of 1.9B. Regarding current trading prices, ME is priced at $0.61, while NEOG trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NEOG's P/E ratio is -3.12. In terms of profitability, ME's ROE is -7.71%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, ME is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NEOG's competition here
ME vs CDNA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, ME is priced at $0.61, while CDNA trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CDNA's P/E ratio is -137.94. In terms of profitability, ME's ROE is -7.71%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, ME is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CDNA's competition here
ME vs PSNL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PSNL has a market cap of 987.5M. Regarding current trading prices, ME is priced at $0.61, while PSNL trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PSNL's P/E ratio is -10.90. In terms of profitability, ME's ROE is -7.71%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, ME is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PSNL's competition here
ME vs CSTL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CSTL has a market cap of 596.3M. Regarding current trading prices, ME is priced at $0.61, while CSTL trades at $19.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CSTL's P/E ratio is -46.81. In terms of profitability, ME's ROE is -7.71%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, ME is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CSTL's competition here
ME vs GRALV Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ME is priced at $0.61, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas GRALV's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to GRALV's ROE of N/A. Regarding short-term risk, ME is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check GRALV's competition here
ME vs FLGT Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, FLGT has a market cap of 531.1M. Regarding current trading prices, ME is priced at $0.61, while FLGT trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas FLGT's P/E ratio is -7.79. In terms of profitability, ME's ROE is -7.71%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, ME is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check FLGT's competition here
ME vs MYGN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MYGN has a market cap of 407.1M. Regarding current trading prices, ME is priced at $0.61, while MYGN trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MYGN's P/E ratio is -1.00. In terms of profitability, ME's ROE is -7.71%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, ME is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MYGN's competition here
ME vs CO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ME is priced at $0.61, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CO's P/E ratio is 5.06. In terms of profitability, ME's ROE is -7.71%, compared to CO's ROE of +0.11%. Regarding short-term risk, ME is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CO's competition here
ME vs PRE Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PRE has a market cap of 356.5M. Regarding current trading prices, ME is priced at $0.61, while PRE trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PRE's P/E ratio is -8.52. In terms of profitability, ME's ROE is -7.71%, compared to PRE's ROE of -0.36%. Regarding short-term risk, ME is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PRE's competition here
ME vs FLDM Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ME is priced at $0.61, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ME's ROE is -7.71%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, ME is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check FLDM's competition here
ME vs NEO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NEO has a market cap of 263.5M. Regarding current trading prices, ME is priced at $0.61, while NEO trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NEO's P/E ratio is -13.14. In terms of profitability, ME's ROE is -7.71%, compared to NEO's ROE of -0.12%. Regarding short-term risk, ME is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NEO's competition here
ME vs OPGN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, ME is priced at $0.61, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas OPGN's P/E ratio is 132.83. In terms of profitability, ME's ROE is -7.71%, compared to OPGN's ROE of +1.58%. Regarding short-term risk, ME and OPGN have similar daily volatility (0.00).Check OPGN's competition here
ME vs IMDX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, IMDX has a market cap of 159.7M. Regarding current trading prices, ME is priced at $0.61, while IMDX trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas IMDX's P/E ratio is -3.94. In terms of profitability, ME's ROE is -7.71%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, ME is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check IMDX's competition here
ME vs GTH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ME is priced at $0.61, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas GTH's P/E ratio is -1.11. In terms of profitability, ME's ROE is -7.71%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ME is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check GTH's competition here
ME vs BDSX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BDSX has a market cap of 124.9M. Regarding current trading prices, ME is priced at $0.61, while BDSX trades at $15.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BDSX's P/E ratio is -3.87. In terms of profitability, ME's ROE is -7.71%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, ME is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BDSX's competition here
ME vs XGN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, XGN has a market cap of 116.5M. Regarding current trading prices, ME is priced at $0.61, while XGN trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas XGN's P/E ratio is -5.36. In terms of profitability, ME's ROE is -7.71%, compared to XGN's ROE of -1.14%. Regarding short-term risk, ME is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check XGN's competition here
ME vs ATLN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ATLN has a market cap of 115.9M. Regarding current trading prices, ME is priced at $0.61, while ATLN trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ATLN's P/E ratio is -1.35. In terms of profitability, ME's ROE is -7.71%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, ME is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ATLN's competition here
ME vs GENE Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ME is priced at $0.61, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas GENE's P/E ratio is -38.25. In terms of profitability, ME's ROE is -7.71%, compared to GENE's ROE of -1.85%. Regarding short-term risk, ME and GENE have similar daily volatility (0.00).Check GENE's competition here
ME vs STIM Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, STIM has a market cap of 108.6M. Regarding current trading prices, ME is priced at $0.61, while STIM trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas STIM's P/E ratio is -2.89. In terms of profitability, ME's ROE is -7.71%, compared to STIM's ROE of -1.65%. Regarding short-term risk, ME is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check STIM's competition here
ME vs SERA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, ME is priced at $0.61, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas SERA's P/E ratio is -3.19. In terms of profitability, ME's ROE is -7.71%, compared to SERA's ROE of -0.41%. Regarding short-term risk, ME is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check SERA's competition here
ME vs DRIO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DRIO has a market cap of 54.8M. Regarding current trading prices, ME is priced at $0.61, while DRIO trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DRIO's P/E ratio is -0.88. In terms of profitability, ME's ROE is -7.71%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, ME is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DRIO's competition here
ME vs STRR Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, STRR has a market cap of 42.7M. Regarding current trading prices, ME is priced at $0.61, while STRR trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas STRR's P/E ratio is -4.62. In terms of profitability, ME's ROE is -7.71%, compared to STRR's ROE of -0.14%. Regarding short-term risk, ME is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check STRR's competition here
ME vs PRPO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PRPO has a market cap of 40.2M. Regarding current trading prices, ME is priced at $0.61, while PRPO trades at $22.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PRPO's P/E ratio is -49.96. In terms of profitability, ME's ROE is -7.71%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, ME is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PRPO's competition here
ME vs STRRP Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, STRRP has a market cap of 33.2M. Regarding current trading prices, ME is priced at $0.61, while STRRP trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas STRRP's P/E ratio is -4.90. In terms of profitability, ME's ROE is -7.71%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, ME is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check STRRP's competition here
ME vs MDXH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MDXH has a market cap of 32.9M. Regarding current trading prices, ME is priced at $0.61, while MDXH trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MDXH's P/E ratio is -0.99. In terms of profitability, ME's ROE is -7.71%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, ME is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MDXH's competition here
ME vs QUCY Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, QUCY has a market cap of 31M. Regarding current trading prices, ME is priced at $0.61, while QUCY trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas QUCY's P/E ratio is -0.11. In terms of profitability, ME's ROE is -7.71%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, ME is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check QUCY's competition here
ME vs AKU Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ME is priced at $0.61, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas AKU's P/E ratio is -0.13. In terms of profitability, ME's ROE is -7.71%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ME is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check AKU's competition here
ME vs CEMI Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ME is priced at $0.61, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ME's ROE is -7.71%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ME and CEMI have similar daily volatility (0.00).Check CEMI's competition here
ME vs ENZ Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, ME is priced at $0.61, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ENZ's P/E ratio is -2.85. In terms of profitability, ME's ROE is -7.71%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, ME is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ENZ's competition here
ME vs PMD Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, ME is priced at $0.61, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PMD's P/E ratio is -5.24. In terms of profitability, ME's ROE is -7.71%, compared to PMD's ROE of -0.32%. Regarding short-term risk, ME and PMD have similar daily volatility (0.00).Check PMD's competition here
ME vs MYNZ Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, ME is priced at $0.61, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, ME's ROE is -7.71%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, ME is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MYNZ's competition here
ME vs VNRX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, VNRX has a market cap of 12.4M. Regarding current trading prices, ME is priced at $0.61, while VNRX trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas VNRX's P/E ratio is -0.54. In terms of profitability, ME's ROE is -7.71%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, ME is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check VNRX's competition here
ME vs CHEK Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, ME is priced at $0.61, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CHEK's P/E ratio is -0.43. In terms of profitability, ME's ROE is -7.71%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, ME is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CHEK's competition here
ME vs BNR Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BNR has a market cap of 10.2M. Regarding current trading prices, ME is priced at $0.61, while BNR trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BNR's P/E ratio is -12.52. In terms of profitability, ME's ROE is -7.71%, compared to BNR's ROE of -0.10%. Regarding short-term risk, ME is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BNR's competition here
ME vs MBAI Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MBAI has a market cap of 9.8M. Regarding current trading prices, ME is priced at $0.61, while MBAI trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MBAI's P/E ratio is 2.53. In terms of profitability, ME's ROE is -7.71%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, ME is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MBAI's competition here
ME vs CNTG Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ME is priced at $0.61, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ME's ROE is -7.71%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ME and CNTG have similar daily volatility (0.00).Check CNTG's competition here
ME vs NOTV Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NOTV has a market cap of 9.1M. Regarding current trading prices, ME is priced at $0.61, while NOTV trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NOTV's P/E ratio is -0.10. In terms of profitability, ME's ROE is -7.71%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, ME is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NOTV's competition here
ME vs BIAF Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BIAF has a market cap of 7.6M. Regarding current trading prices, ME is priced at $0.61, while BIAF trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BIAF's P/E ratio is -0.36. In terms of profitability, ME's ROE is -7.71%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, ME is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BIAF's competition here
ME vs TRIB Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, TRIB has a market cap of 7.6M. Regarding current trading prices, ME is priced at $0.61, while TRIB trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas TRIB's P/E ratio is -0.37. In terms of profitability, ME's ROE is -7.71%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, ME is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check TRIB's competition here
ME vs APDN Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, ME is priced at $0.61, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas APDN's P/E ratio is -0.10. In terms of profitability, ME's ROE is -7.71%, compared to APDN's ROE of -6.53%. Regarding short-term risk, ME is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check APDN's competition here
ME vs NVTA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ME is priced at $0.61, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ME's ROE is -7.71%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ME is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NVTA's competition here
ME vs LMDX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ME is priced at $0.61, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ME's ROE is -7.71%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ME is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check LMDX's competition here
ME vs LMDXW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ME is priced at $0.61, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ME's ROE is -7.71%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ME is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check LMDXW's competition here
ME vs ADVB Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ADVB has a market cap of 4.7M. Regarding current trading prices, ME is priced at $0.61, while ADVB trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ADVB's P/E ratio is 1.08. In terms of profitability, ME's ROE is -7.71%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, ME is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ADVB's competition here
ME vs BGLC Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BGLC has a market cap of 4.4M. Regarding current trading prices, ME is priced at $0.61, while BGLC trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BGLC's P/E ratio is -1.46. In terms of profitability, ME's ROE is -7.71%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, ME is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BGLC's competition here
ME vs BNGO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BNGO has a market cap of 4.1M. Regarding current trading prices, ME is priced at $0.61, while BNGO trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BNGO's P/E ratio is -0.28. In terms of profitability, ME's ROE is -7.71%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, ME is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BNGO's competition here
ME vs NDRA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NDRA has a market cap of 3.8M. Regarding current trading prices, ME is priced at $0.61, while NDRA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NDRA's P/E ratio is -0.62. In terms of profitability, ME's ROE is -7.71%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, ME is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NDRA's competition here
ME vs DMTK Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ME is priced at $0.61, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ME's ROE is -7.71%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, ME is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DMTK's competition here
ME vs SQL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ME is priced at $0.61, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas SQL's P/E ratio is -0.40. In terms of profitability, ME's ROE is -7.71%, compared to SQL's ROE of +2.74%. Regarding short-term risk, ME is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check SQL's competition here
ME vs AWH Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, ME is priced at $0.61, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas AWH's P/E ratio is -0.09. In terms of profitability, ME's ROE is -7.71%, compared to AWH's ROE of +2.03%. Regarding short-term risk, ME and AWH have similar daily volatility (0.00).Check AWH's competition here
ME vs INBS Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, ME is priced at $0.61, while INBS trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas INBS's P/E ratio is -0.22. In terms of profitability, ME's ROE is -7.71%, compared to INBS's ROE of -1.74%. Regarding short-term risk, ME is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check INBS's competition here
ME vs HTGM Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ME is priced at $0.61, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ME's ROE is -7.71%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ME and HTGM have similar daily volatility (0.00).Check HTGM's competition here
ME vs BIAFW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BIAFW has a market cap of 894.9K. Regarding current trading prices, ME is priced at $0.61, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BIAFW's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, ME and BIAFW have similar daily volatility (0.00).Check BIAFW's competition here
ME vs BIOC Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ME is priced at $0.61, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ME's ROE is -7.71%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ME is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BIOC's competition here
ME vs ISPC Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, ISPC has a market cap of 426.3K. Regarding current trading prices, ME is priced at $0.61, while ISPC trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas ISPC's P/E ratio is -0.01. In terms of profitability, ME's ROE is -7.71%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, ME is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check ISPC's competition here
ME vs PRENW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PRENW has a market cap of 224.8K. Regarding current trading prices, ME is priced at $0.61, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PRENW's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, ME is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PRENW's competition here
ME vs SQLLW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, ME is priced at $0.61, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, ME's ROE is -7.71%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, ME is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check SQLLW's competition here
ME vs TTOO Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, TTOO has a market cap of 56.1K. Regarding current trading prices, ME is priced at $0.61, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas TTOO's P/E ratio is -0.07. In terms of profitability, ME's ROE is -7.71%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, ME and TTOO have similar daily volatility (0.00).Check TTOO's competition here
ME vs OCDX Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ME's ROE is -7.71%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ME is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check OCDX's competition here
ME vs PRXL Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas PRXL's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, ME is less volatile compared to PRXL. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check PRXL's competition here
ME vs DHR-PA Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ME's ROE is -7.71%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, ME is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check DHR-PA's competition here
ME vs NDRAW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas NDRAW's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, ME is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check NDRAW's competition here
ME vs MEUSW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, ME is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check MEUSW's competition here
ME vs BNGOW Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas BNGOW's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, ME is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check BNGOW's competition here
ME vs CHEKZ Comparison June 2026
ME plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ME stands at 15.3M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, ME is priced at $0.61, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ME currently has a P/E ratio of -0.03, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, ME's ROE is -7.71%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, ME is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for ME.Check CHEKZ's competition here